Hope for Surviving Oral Cancer
Links shared publicly online about this topic.
- 789total visits
Hope for Surviving Oral Cancer
View full resource at fightoralcancer.org
Tags: Cancer
Most Recently Shared on October 19, 2010 at 7:59 pm By:
Hope for Surviving Oral Cancer http://ow.ly/2W4c6
Prevalidation of Salivary Biomarkers for Oral Cancer Detection | Oral Cancer News
oralcancernews.org — “Prevalidation of Salivary Biomarkers for Oral Cancer Detection | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on March 29, 2012 at 7:06 pm By:
More Americans Are Surviving Cancer - History, Treatment of Cancer - AARP
aarp.org — “More Americans are surviving. Here's why.” View full resource at aarp.org
Most Recently Shared on March 29, 2012 at 5:04 pm By:
elaine schattner Internist, Oncologist, Hematologist, Physician, and Doctor
MT @UCPritzker: Richard Schilsky, on what makes cancer such a fierce opponent, @AARP - http://t.co/CGK8zbWJ
Wider Surgical Margins Better for Early Tongue Cancer | Oral Cancer News
oralcancernews.org — “Wider Surgical Margins Better for Early Tongue Cancer | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on March 22, 2012 at 12:18 pm By:
Court: Tobacco Health Labels Constitutional | Oral Cancer News
oralcancernews.org — “Court: Tobacco Health Labels Constitutional | Oral Cancer News” View full resource at oralcancernews.org
Most Recently Shared on March 21, 2012 at 1:43 pm By:
Vemurafenib Extends Survival To 16 Months For Some Patients With Metastatic Melanoma
medicalnewstoday.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX40” View full resource at medicalnewstoday.com
Most Recently Shared on March 20, 2012 at 7:05 am By:
Vemurafenib Extends Survival To 16 Months For Some Patients With Metastatic Melanoma http://t.co/4ADvhzXF #skincancer #melanoma
Common Ground-Hope for Prostate Cancer at Johns Hopkins Medicine - YouTube
youtube.com — “Steve Lucido survived prostate cancer and feels it was due to the expertise of his surgeon Dr. Ted Schaeffer. Learn why Johns Hopkins is at the forefront of ...” View full resource at youtube.com
Most Recently Shared on March 17, 2012 at 12:00 pm By:
JohnsHopkinsMedicine Health News
Steve Lucido believes he survived #prostate #cancer due to the expertise of his Hopkins surgeon. Watch his story. http://t.co/N36mi9EX
Oral BRAF inhibitor can extend survival to 16 months for patients with MM
news-medical.net — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation.” View full resource at news-medical.net
Most Recently Shared on March 17, 2012 at 9:26 am By:
Oral BRAF inhibitor can extend survival to 16 months for patients with MM: An international team of researchers ... http://t.co/tM2N1Vwa
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
newswise.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.” View full resource at newswise.com
Most Recently Shared on March 16, 2012 at 4:47 pm By:
#health news: Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib http://t.co/NOOLgphV
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib
newswise.com — “An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center, have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive, prolonged responses and a median survival of almost 16 months.” View full resource at newswise.com
Most Recently Shared on March 16, 2012 at 4:42 pm By:
newswise Health Communicator and Health News
Response Rate High for Some Patients with Metastatic Melanoma Treated with Vemurafenib http://t.co/J4PYO8lL
BBC News - Skin cancer drug hopes raised by study
bbc.co.uk — “A new treatment for advanced skin cancer almost doubles survival times, according to an international study.” View full resource at bbc.co.uk
Most Recently Shared on February 23, 2012 at 2:30 am By:
Richard G. Lanzara Health Professional
BBC News - Skin cancer drug hopes raised by study http://t.co/vLfIrn9d #science #biology #medicine #cancer
New treatment doubles survival for certain brain tumor patients - USATODAY.com
yourlife.usatoday.com — “In a victory for personalized medicine, new treatment doubles survival for brain tumor patients with genetic mutation.” View full resource at yourlife.usatoday.com
Most Recently Shared on January 23, 2012 at 1:30 pm By:
Jack A. Roth, M.D. Doctor, Surgeon, and Physician
Chemotherapy can double survival time for certain brain tumors http://t.co/POsTlyBd
Bone Drug Zometa Boosts Breast Cancer Survival as Much as Chemo - - TIME Healthland
healthland.time.com — “Doctors were mostly hoping to prevent complications and relapses when they gave young women a medicine to keep their bones strong during breast cancer treatment. Seven years later, they found it did more than that: The bone drug improved survival, as much as many chemotherapies do.” View full resource at healthland.time.com
Most Recently Shared on December 9, 2011 at 9:15 pm By:
A study shows that this bone drug boosts breast cancer survival rates | http://t.co/AvveHsUI
New Book is First to Examine Cancer Disparities and Offer Interventions
prweb.com — “"Cancer Disparities: Causes and Evidence-Based Solutions" is the first book to examine the racial, socioeconomic, and biological factors that influence cancer incidence and survival, and is a major contribution to the cancer and health disparities field. This title is co-published by the American Cancer Society and Springer Publishing Company, and edited by Drs. Ronit Elk and Hope Landrine.” View full resource at prweb.com
Most Recently Shared on December 9, 2011 at 2:55 pm By:
Springer Publishing Health Business
Check out our press release on our new book, Cancer Disparities, co-published with the American Cancer Society: http://t.co/qakV36dv
Study: Bone drug boosts breast cancer survival - Topix
topix.com — “Study: Bone drug boosts breast cancer survival - Topix” View full resource at topix.com
Most Recently Shared on December 9, 2011 at 2:02 am By:
Study: Bone drug boosts breast cancer survival: Doctors were mostly hoping to prevent complications and relapses... http://t.co/51HeYz1G
Breast-Cancer Drugs Raise Hopes - WSJ.com
online.wsj.com — “Two drugs significantly extend the time that women with advanced breast cancer can live without their tumors growing, potentially changing the landscape for 80% of patients with the disease, according to two separate studies.” View full resource at online.wsj.com
Most Recently Shared on December 8, 2011 at 3:18 am By:
Tom Heston, MD Physician, Doctor, and Family Medicine Doctor
Drugs Keep Tumors at Bay - Wall Street Journal http://t.co/VZDNPMGU #medicine
Advertisement
